Zydus gains final USFDA approval for Valbenazine Capsules
Valbenazine Capsules had annual sales of $ 1,993.6 million in the United States (IQVIA MAT June 2024)
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
tardive dyskinesia
Lupin gets tentative US FDA approval for Valbenazine capsules
Valbenazine is indicated for the treatment of tardive dyskinesia (uncontrollable movement of face, tongue, or other body parts)